Chartwell Partners Recruits Andy Stober As Chief Manufacturing Officer For Encoded Therapeutics

Chartwell Partners is pleased to announce the recruitment of Andy Stober as Chief Manufacturing Officer for Encoded Therapeutics, a South San Francisco based precision gene therapy company. Encoded recently announced a $104M Series C financing and has been funded to date with world class venture companies including Venrock, ARCH Venture Partners, Matrix Capital Management, and Illumina Ventures. Andy brings a wealth of gene therapy manufacturing expertise from AveXis where he helped to lead the company’s transition from R&D stage through to the commercialization of Zolgensma, the first gene therapy approved to treat children less than two years of age with spinal muscular atrophy (SMA), the most severe form of SMA and a leading genetic cause of infant mortality. Prior to AveXis, Andy served in multiple senior manufacturing roles at Biogen, Amgen and Merck & Co.

Official press release from Encoded Therapeutics –